UMB Bank n.a. Has $29,000 Stock Holdings in Hologic, Inc. $HOLX

Key Points

• UMB Bank n.a. has reduced its holdings in Hologic, Inc. by 90.4% during Q2, owning 447 shares valued at $29,000 after selling 4,219 shares.
• Several institutional investors have increased their positions in Hologic, with Victory Capital Management now holding 6.6 million shares worth $408.3 million after a 34.4% increase.
• Hologic reported Q3 earnings of $1.08 per share, surpassing estimates, with revenue of $1.02 billion, and has set EPS guidance for Q4 2025 between 1.090-1.120.

UMB Bank n.a. trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 90.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 447 shares of the medical equipment provider's stock after selling 4,219 shares during the quarter. UMB Bank n.a.'s holdings in Hologic were worth $29,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Victory Capital Management Inc. increased its position in Hologic by 34.4% during the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock worth $408,283,000 after buying an additional 1,692,177 shares during the last quarter. Invesco Ltd. increased its position in Hologic by 18.8% during the first quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock worth $298,655,000 after buying an additional 764,573 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Hologic by 1.6% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider's stock worth $276,303,000 after buying an additional 69,878 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in Hologic by 0.8% during the first quarter. Ameriprise Financial Inc. now owns 3,512,594 shares of the medical equipment provider's stock valued at $216,973,000 after acquiring an additional 29,133 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Hologic by 8.1% in the first quarter. Dimensional Fund Advisors LP now owns 2,838,656 shares of the medical equipment provider's stock valued at $175,331,000 after purchasing an additional 213,366 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Performance

NASDAQ HOLX opened at $67.21 on Friday. The firm has a market cap of $14.95 billion, a price-to-earnings ratio of 27.89, a PEG ratio of 2.38 and a beta of 0.57. The company has a 50 day moving average of $66.76 and a 200-day moving average of $62.86. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.03. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company's revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the business posted $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Mizuho set a $75.00 price target on Hologic in a research report on Thursday, July 31st. Stephens reaffirmed an "overweight" rating and issued a $78.00 price target on shares of Hologic in a research report on Thursday, September 18th. Evercore ISI increased their target price on shares of Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Argus increased their target price on shares of Hologic from $80.00 to $90.00 and gave the company a "buy" rating in a research note on Friday, September 19th. Finally, UBS Group increased their target price on shares of Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research note on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $79.38.

Insider Buying and Selling at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the firm's stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the sale, the chief executive officer owned 1,234,624 shares of the company's stock, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.88% of the company's stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.